| |  Online-Ressource |
|---|
| Verfasst von: | Benza, Raymond L. [VerfasserIn]  |
|---|
| | Langleben, David [VerfasserIn] |
|---|
| | Hemnes, Anna R. [VerfasserIn] |
|---|
| | Noordegraaf, Anton Vonk [VerfasserIn] |
|---|
| | Rosenkranz, Stephan [VerfasserIn] |
|---|
| | Thenappan, Thenappan [VerfasserIn] |
|---|
| | Hassoun, Paul M. [VerfasserIn] |
|---|
| | Preston, Ioana R. [VerfasserIn] |
|---|
| | Ghio, Stefano [VerfasserIn] |
|---|
| | Badagliacca, Roberto [VerfasserIn] |
|---|
| | Vizza, Carmine D. [VerfasserIn] |
|---|
| | Lang, Irene M. [VerfasserIn] |
|---|
| | Meier, Christian [VerfasserIn] |
|---|
| | Grünig, Ekkehard [VerfasserIn] |
|---|
| Titel: | Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension |
|---|
| Verf.angabe: | Raymond L. Benza, David Langleben, Anna R. Hemnes, Anton Vonk Noordegraaf, Stephan Rosenkranz, Thenappan Thenappan, Paul M. Hassoun, Ioana R. Preston, Stefano Ghio, Roberto Badagliacca, Carmine D. Vizza, Irene M. Lang, Christian Meier and Ekkehard Grünig |
|---|
| E-Jahr: | 2022 |
|---|
| Jahr: | [2022] |
|---|
| Umfang: | 12 S. |
|---|
| Illustrationen: | Illustrationen |
|---|
| Fussnoten: | Gesehen am 01.02.2023 |
|---|
| Titel Quelle: | Enthalten in: European respiratory review |
|---|
| Ort Quelle: | Sheffield : Soc., 2005 |
|---|
| Jahr Quelle: | 2022 |
|---|
| Band/Heft Quelle: | 31(2022), 166, Artikel-ID 220061, Seite 1-12 |
|---|
| ISSN Quelle: | 1600-0617 |
|---|
| Abstract: | Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are progressive diseases that can lead to right heart failure and death. Right ventricular dysfunction, hypertrophy and maladaptive remodelling are consequences of increased right ventricular (RV) afterload in PAH and CTEPH and are indicative of long-term outcomes. Because RV failure is the main cause of morbidity and mortality in PAH and CTEPH, successful treatments should lead to improvements in RV parameters. Riociguat is a soluble guanylate cyclase stimulator approved for the treatment of PAH and inoperable or persistent/recurrent CTEPH after pulmonary endarterectomy. This review examines the current evidence showing the effect of riociguat on the right ventricle, with particular focus on remodelling, function and structural parameters in preclinical models and patients with PAH or CTEPH. - Tweetable abstract ERSpublications - click to tweetRaymond L. Benza (@OSUWexMed) and co-authors review the current evidence showing the effect of riociguat on right ventricle remodelling, function and structural parameters in preclinical models and patients with #PAH or #CTEPH. #pulmonaryhypertension https://bit.ly/3Q9icVm |
|---|
| DOI: | doi:10.1183/16000617.0061-2022 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1183/16000617.0061-2022 |
|---|
| | Volltext: https://err.ersjournals.com/content/31/166/220061 |
|---|
| | DOI: https://doi.org/10.1183/16000617.0061-2022 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| K10plus-PPN: | 1832876128 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension / Benza, Raymond L. [VerfasserIn]; [2022] (Online-Ressource)
